146 related articles for article (PubMed ID: 32450563)
1. Risk Factors for Adverse Events in Patients with Chronic Constipation Following Lubiprostone Administration.
Eguchi T; Yoshizaki T; Takagi M; Ikeoka S; Hashimura H; Okamoto N; Matsumoto M; Matsuda T; Miura T; Momose K; Otsuka T; Morisawa T; Okada A
Dig Dis; 2021; 39(1):10-15. PubMed ID: 32450563
[TBL] [Abstract][Full Text] [Related]
2. Real-World Comparison of Elobixibat and Lubiprostone Treatment in Patients with Chronic Constipation: A Propensity Score-Matched Analysis.
Eguchi T; Yoshizaki T; Ikeoka S; Takagi M; Fujinami M; Matsuda T; Yamaguchi T; Nonaka T; Amioka S; Katayama N; Inoue K; Matsumoto M; Momose K; Sako T; Noda M; Morisawa T; Okada A
Dig Dis; 2021; 39(4):341-350. PubMed ID: 33142288
[TBL] [Abstract][Full Text] [Related]
3. Open-label study to evaluate the treatment continuation rate after a dose reduction of lubiprostone due to onset of adverse events.
Ohbayashi H; Sato Y; Kiuchi M; Asano T; Nagazumi A; Kimura T
Expert Rev Gastroenterol Hepatol; 2021 Mar; 15(3):333-342. PubMed ID: 33206011
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of efficacy and safety of lubiprostone in patients with chronic constipation.
Handa Y; Fukushima S; Yo S; Osawa M; Murao T; Handa O; Matsumoto H; Umegaki E; Shiotani A
Scand J Gastroenterol; 2021 Oct; 56(10):1140-1145. PubMed ID: 34423734
[TBL] [Abstract][Full Text] [Related]
5. The Efficacy and Safety of Lubiprostone for Constipation in Cancer Patients Compared with Non-cancer Patients: A Retrospective Cohort Study.
Sada H; Kajizono M; Ushio S; Esumi S; Kitamura Y; Sendo T
Biol Pharm Bull; 2020; 43(11):1699-1706. PubMed ID: 33132315
[TBL] [Abstract][Full Text] [Related]
6. Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis.
Kawada K; Ohta T; Fukuda H; Hayashi T; Tanaka K; Imai T; Morita Y; Miyamura M
Ann Hematol; 2020 Oct; 99(10):2429-2436. PubMed ID: 32839869
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the impact on efficacy of lubiprostone dose reduction to manage adverse events in the treatment of chronic constipation in Japan.
Ohbayashi H; Sato Y; Kiuchi M; Nagazumi A; Kanzo T; Kimura T
Expert Rev Gastroenterol Hepatol; 2022 Aug; 16(8):809-817. PubMed ID: 35993999
[TBL] [Abstract][Full Text] [Related]
8. Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Li F; Fu T; Tong WD; Liu BH; Li CX; Gao Y; Wu JS; Wang XF; Zhang AP
Mayo Clin Proc; 2016 Apr; 91(4):456-68. PubMed ID: 27046523
[TBL] [Abstract][Full Text] [Related]
9. Evaluation and Comparison of Daiokanzoto and Lubiprostone for Constipation: A Retrospective Cohort Study.
Yoshida A; Hirose T; Kuroda A; Mitsuoka M; Shinoda Y; Mori K; Kawachi Y; Tanaka K; Takeda A; Sugiyama T; Yoshimura T
Biol Pharm Bull; 2019; 42(5):680-684. PubMed ID: 31061310
[TBL] [Abstract][Full Text] [Related]
10. Safety of elobixibat and lubiprostone in Japanese patients with chronic constipation: a retrospective cohort study.
Ooba N; Takahashi Y; Nagamura M; Takahashi M; Ushida M; Kawakami E; Kimura M; Sato T; Tokuyoshi J; Miyazaki C; Shimada M
Expert Opin Drug Saf; 2021 Dec; 20(12):1553-1558. PubMed ID: 34281471
[TBL] [Abstract][Full Text] [Related]
11. Novel Oral Therapies for Opioid-induced Bowel Dysfunction in Patients with Chronic Noncancer Pain.
Holder RM; Rhee D
Pharmacotherapy; 2016 Mar; 36(3):287-99. PubMed ID: 26945548
[TBL] [Abstract][Full Text] [Related]
12. Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial.
Kessoku T; Imajo K; Kobayashi T; Ozaki A; Iwaki M; Honda Y; Kato T; Ogawa Y; Tomeno W; Kato S; Higurashi T; Yoneda M; Kirikoshi H; Kubota K; Taguri M; Yamanaka T; Usuda H; Wada K; Kobayashi N; Saito S; Nakajima A
Lancet Gastroenterol Hepatol; 2020 Nov; 5(11):996-1007. PubMed ID: 32805205
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders.
Cryer B; Drossman DA; Chey WD; Webster L; Habibi S; Wang M
Dig Dis Sci; 2017 Dec; 62(12):3568-3578. PubMed ID: 28849329
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation.
Lembo AJ; Johanson JF; Parkman HP; Rao SS; Miner PB; Ueno R
Dig Dis Sci; 2011 Sep; 56(9):2639-45. PubMed ID: 21769655
[TBL] [Abstract][Full Text] [Related]
15. A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain.
Jamal MM; Adams AB; Jansen JP; Webster LR
Am J Gastroenterol; 2015 May; 110(5):725-32. PubMed ID: 25916220
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with long-term efficacy of lubiprostone for chronic constipation.
Morise T; Fukuzawa M; Sugimoto M; Nagata N; Kono S; Yamauchi Y; Sugimoto A; Uchida K; Koyama Y; Madarame A; Yamaguchi H; Matsumoto T; Kagawa Y; Kawai T; Itoi T
J Clin Biochem Nutr; 2023 Jul; 73(1):91-96. PubMed ID: 37534090
[TBL] [Abstract][Full Text] [Related]
17. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation.
Chey WD; Drossman DA; Johanson JF; Scott C; Panas RM; Ueno R
Aliment Pharmacol Ther; 2012 Mar; 35(5):587-99. PubMed ID: 22251419
[TBL] [Abstract][Full Text] [Related]
18. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety.
Johanson JF; Ueno R
Aliment Pharmacol Ther; 2007 Jun; 25(11):1351-61. PubMed ID: 17509103
[TBL] [Abstract][Full Text] [Related]
19. Lubiprostone for the treatment of functional constipation in children.
Hyman PE; Di Lorenzo C; Prestridge LL; Youssef NN; Ueno R
J Pediatr Gastroenterol Nutr; 2014 Mar; 58(3):283-91. PubMed ID: 24048162
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Lubiprostone for the Treatment of Opioid-Induced Constipation, Analyzed by Opioid Class.
Webster LR; Brewer RP; Lichtlen P; Losch-Beridon T; Mareya S; Wang M
Pain Med; 2018 Jun; 19(6):1195-1205. PubMed ID: 29897589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
